Resistance to activated protein C: role in venous and arterial thrombosis
| Autor: | Martine Aiach, Martine Alhenc-Gelas, Joseph Emmerich, JN Fiessinger |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male medicine.medical_specialty Arginine Thrombophilia Internal medicine medicine Coagulopathy Humans Aged Pharmacology biology business.industry Factor V Thrombosis General Medicine Middle Aged Thrombophlebitis medicine.disease Enzyme Activation Venous thrombosis Endocrinology biology.protein Activated protein C resistance business Protein C medicine.drug |
| Zdroj: | Biomedicine & Pharmacotherapy. 50:254-260 |
| ISSN: | 0753-3322 |
| Popis: | Summary Activated protein C resistance is the most prevalent cause of thrombophilia: it is found in 20 to 30% of patients with a deep venous thrombosis history. Activated protein C resistance is due to an arginine 506 to glutamine mutation in factor V. This mutation prevents normal inactivation of activated factor V by activated protein C. The estimated increase in relative risk of venous thrombosis is 5- to 10-fold in heterozygotes, and 50- to 100-fold in homozygotes. Activated protein C resistance does not seem to play a role in arterial thrombosis and in the occurrence of myocardial infarction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect